Equillium Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
EQ$1.46-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Additional · AccumulatedOther · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2021 | 29,455,668 | $2 | $176,618 | $(138) | $(109,977) | $66,505 |
| Issuance of common stock for Bioniz acquisition | 4,820,230 | 1 | 22,541 | - | - | 22,542 |
| Issuance of common stock under employee stock purchase plan | 138,251 | - | 215 | - | - | 215 |
| Vesting of restricted stock liability | - | - | 53 | - | - | 53 |
| Stock-based compensation expense | - | - | 4,841 | - | - | 4,841 |
| Comprehensive income | - | - | - | 214 | - | 214 |
| Net loss | - | - | - | - | (62,428) | (62,428) |
| Balance at December 31, 2022 | 34,414,149 | $3 | $204,268 | $76 | $(172,405) | $31,942 |
| Issuance of common stock for Bioniz acquisition | 849,133 | - | - | - | - | - |
| Issuance of common stock under employee stock purchase plan | 289,855 | - | 165 | - | - | 165 |
| Common stock repurchased | (298,385) | - | (260) | - | - | (260) |
| Stock-based compensation expense | - | - | 3,997 | - | - | 3,997 |
| Comprehensive income | - | - | - | 64 | - | 64 |
| Net loss | - | - | - | - | (13,335) | (13,335) |
| Balance at December 31, 2023 | 35,254,752 | $3 | $208,170 | $140 | $(185,740) | $22,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.